- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02101970
Weight Loss Plus Omega-3 Fatty Acids or Placebo in High Risk Women
January 6, 2022 updated by: Carol Fabian, MD
Randomized Pilot Trial of Omega-3 Fatty Acids or Placebo in Peri- or Post-Menopausal Women at High Risk for Breast Cancer Undergoing a Weight Loss Intervention
The purpose of this study is to determine if high dose supplementation with the omega-3 fatty acids EPA and DHA, when added to a weight loss program, is well tolerated in the study population and if there is an increase in the favorable change in blood and tissue breast cancer risk factors when compared to weight loss alone.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Subjects will all participate in a 6-month weight loss intervention.
Subjects will be randomized to receive either blinded placebo or omega-3 fatty acids for 6 months.
Study Type
Interventional
Enrollment (Actual)
46
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Kansas
-
Kansas City, Kansas, United States, 66205
- University of Kansas Medical Center, Breast Cancer Prevention Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
45 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Evidence of Hyperplasia with Masood score of 13 or higher and 500 or more epithelial cells on cytology slide of screening Random Periareolar Fine Needle Aspiration (RPFNA)
- Access to smart phone and or computer
- Willing to comply with diet, exercise and lifestyle modification during weight reduction and maintenance phase.
- Willing to start the dietary and exercise intervention within 9 months of RPFNA
- Willing to complete quality of life questionnaires at multiple visits
- Willing to have a medical history and physical at multiple visits
- Willing to have an additional RPFNA at two additional visits
- Be willing to have blood drawn at multiple visits
- Willing to sign and able to understand consent for the RPFNA's and study participation
- Reasonable hematopoetic, kidney and liver function consistent with safe participation on this trial.
Exclusion Criteria:
- Having taken medications that seriously affect metabolism such as steroids, dexatrim or other diet drugs within 3 weeks of study registration
- Have changed dose or type of hormone supplementation within 3 months
- Currently receiving other investigational agents
- Have been on a chemoprevention trial within 6 months or taken a Selective Estrogen Receptor Modulator or aromatase inhibitor within last 6 months.
- Need for chronic use of aspirin, nonsteroidal anti-inflamatory drug (NSAID) or other anti-inflammatory agents
- Taking metformin, or other diabetes medications
- Taking statins
- Unable to participate in moderate intensity exercise (walking, treadmill, elliptical, water aerobics)
- Would be unable to participate, by phone, in weekly phone call sessions
- Cells suspicious for malignancy as assessed by cytotechnologist or cytopathologist.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Weight Loss + Omega-3 FA
Participants will be instructed to follow a diet that is reduced by 500-700 kcal/day below maintenance requirements for 24 weeks or until the individual has reached a BMI of 25kg/m2 (generally 1000-2000 calories/day).
Participants will be given one capsule of Omega-3 FA (fatty acids) a day beginning 2 weeks after starting their diet and exercise routine.
Omega-3 FA will be increased by 1 capsule/day or every other day until participant is taking 5 capsules per day.Each Amber 4020 Ethyl Ester (EE) 1000 mg omega-3 capsule contains 420 mg of EPA and 210 mg of DHA both as the ethyl esters (380 mg EPA and 190 mg DHA)
|
Amber 4020 Ethyl Ester (EE) 1000 mg omega-3 capsule contains 420 mg of EPA and 210 mg of DHA both as the ethyl esters (380 mg EPA and 190 mg DHA)
Other Names:
Increasing physical activity required over 6 month period to be tracked by a Fitbit.
Diet based on caloric intake and eating approved foods.
|
Active Comparator: Weight Loss + Placebo
Participants will be instructed to exercise and follow a diet that is reduced by 500-700 kcal/day below maintenance requirements for 24 weeks or until the individual has reached a BMI of 25kg/m2 (generally 1000-2000 calories/day).
Participants will be given one capsule of placebo a day beginning 2 weeks after starting their diet and exercise routine.
Placebo capsule will be increased by 1 capsule/day or every other day until participant is taking 5 capsules per day.
|
Increasing physical activity required over 6 month period to be tracked by a Fitbit.
Diet based on caloric intake and eating approved foods.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dropout rate
Time Frame: Up to 6 Months
|
Measured as the number of participants that dropout before diet+intervention period is complete
|
Up to 6 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Study design feasibility
Time Frame: Up to 6 months
|
Based on eligibility criteria, study procedures and participation of subjects the study design will be measured to see if it will practically work with a larger study population
|
Up to 6 months
|
Modulation of breast cancer risk biomarkers
Time Frame: Change from Baseline to 6 Months
|
Measure the change in fasting and postprandial blood inflammatory, and risk biomarkers
|
Change from Baseline to 6 Months
|
Modulation of breast cancer risk biomarkers in benign breast tissue
Time Frame: Change from Baseline to 6 Months
|
Measure change in fasting and postprandial blood inflammatory, and risk biomarkers
|
Change from Baseline to 6 Months
|
Modulation of breast cancer risk biomarkers
Time Frame: Change from Baseline to 12 Months
|
Measure the change in fasting and postprandial blood inflammatory, and risk biomarkers
|
Change from Baseline to 12 Months
|
Modulation of breast cancer risk biomarkers in benign breast tissue
Time Frame: Change from Baseline to 12 Months
|
Measure change in fasting and postprandial blood inflammatory, and risk biomarkers
|
Change from Baseline to 12 Months
|
Weight gain
Time Frame: Change from 6 Months to 12 Months
|
Measure change in weight in participants during the 6-12 month maintenance phase
|
Change from 6 Months to 12 Months
|
Change in Gut Microbiome
Time Frame: Change from Baseline to Month 6
|
Change in eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA):arachidonic acid (AA) ratio
|
Change from Baseline to Month 6
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Carol J. Fabian, M.D., University of Kansas Medical Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 1, 2014
Primary Completion (Actual)
May 1, 2016
Study Completion (Actual)
August 27, 2018
Study Registration Dates
First Submitted
March 28, 2014
First Submitted That Met QC Criteria
March 28, 2014
First Posted (Estimate)
April 2, 2014
Study Record Updates
Last Update Posted (Actual)
January 24, 2022
Last Update Submitted That Met QC Criteria
January 6, 2022
Last Verified
January 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00000703
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
Global results will be published.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
Clinical Trials on Omega-3 Fatty Acids
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedBreast Neoplasms | ArthralgiaUnited States
-
S.LAB (SOLOWAYS)Center of New Medical Technologies; Triangel ScientificCompletedLDL Hyperlipoproteinemia | Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia | Triglyceride Storage Type I or II DiseaseRussian Federation
-
Mayo ClinicNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaboratorsCompleted
-
Wen-Chih WuWithdrawnSteatosis | Right Ventricular Failure | Pulmonary; HypertensionUnited States
-
University of California, San FranciscoAutism SpeaksCompleted
-
Pennington Biomedical Research CenterCompleted
-
Evandro Chagas Institute of Clinical ResearchAndrea Silvestre de Sousa, MD PhD; Pedro Emmanuel Alvarenga Americano do Brasil... and other collaboratorsCompletedChagas CardiomyopathyBrazil
-
Hugo W. Moser Research Institute at Kennedy Krieger...University of California, San FranciscoCompletedAutism Spectrum Disorders | HyperactivityUnited States
-
Retina Foundation of the SouthwestDSM Nutritional Products, Inc.CompletedInfant DevelopmentUnited States
-
Centre for Chronic Disease Control, IndiaCompleted